Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India and internationally. It operates through Manufacturing and Dealing in Pharmaceutical Drug and Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, dry syrups and suspensions, creams, gel, ORS, jelly, gynae, inhalers, opthal, ortho, and pediatrics formulations in dosage forms. It also provides life care, evolve, and the right nutrition products under the Cratus brand. In addition, the company offers its pharmaceutical formulation products in various dosage forms, such as tablets, capsules, ointments, injections, liquids orals, and effervescent. Syncom Formulations (India) Limited was incorporated in 1988 and is based in Indore, India.
| Current Price | ₹14.94 |
|---|---|
| Market Cap | ₹1,404 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Products |
| P/E Ratio | 18.4 |
| Return on Equity | 20.19% |
| 52-Week Range | ₹10.21 – ₹22.64 |
| Beta (1Y) | 1.19 |
| Dividend Yield | 0.00% |
Syncom Formulations (India) Ltd is trading at ₹14.94, with a market capitalisation of ₹1,404 Cr.
Syncom Formulations (India) Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Products).
Syncom Formulations (India) Ltd has a P/E of 18.4 and a return on equity of 20.19%.